ACM
CCXI

AlphaCrest Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

AlphaCrest Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,389
Closed -$629K – 1426
2022
Q2 		$629K Buy
25,389
+14,187
+127% +$313K 0.03% 874
2022
Q1 		$281K Sell
11,202
-2,898
-21% -$81.4K 0.02% 1125
2021
Q4 		$513K Buy
+14,100
New +$495K 0.02% 1088
2021
Q3 		– Sell
-22,919
Closed -$307K – 1424
2021
Q2 		$307K Buy
22,919
+9,919
+76% +$244K 0.01% 1098
2021
Q1 		$666K Buy
+13,000
New +$782K 0.04% 666

Other funds holding CCXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

AlphaCrest Capital Management's CCXI Position: Q3 2022 in Review

AlphaCrest Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 25,389 shares — an estimated $629K sold.

AlphaCrest Capital Management first reported a position in CCXI in Q1 2021 and held it in 5 quarters. The position peaked at $666K in Q1 2021. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

  • AlphaCrest Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 25,389 ChemoCentryx, Inc. shares in Q3 2022, an estimated $629K.
  • AlphaCrest Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2021 and held it in 5 quarters.
  • AlphaCrest Capital Management's ChemoCentryx, Inc. position peaked at $666K in Q1 2021.
  • 217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on AlphaCrest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.